These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8500920)

  • 21. Evaluation of the bioequivalence of capsules containing 150 mg of fluconazole.
    Porta V; Chang KH; Storpirtis S
    Int J Pharm; 2005 Jan; 288(1):81-6. PubMed ID: 15607260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule.
    Schaltenbrand R; Huber R; Cotoraci CA; Mascher H; Potthast H; Hole U
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):453-9. PubMed ID: 11680670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
    Cho HY; Moon JD; Lee YB
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence of two oral immediate release formulations of pindolol in healthy volunteers assessed by ratio analysis.
    Koch HJ; Raschka C; Hannak D
    Acta Physiol Pharmacol Bulg; 2000; 25(3-4):99-102. PubMed ID: 11688554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence evaluation of 2 different oral formulations of ciprofloxacin in healthy volunteers.
    Galicia I; Frias-Iniesta J; Carcas AJ; Soto A; Gomez E; Miranda E; Fernandez A; Montuenga C
    Int J Clin Pharmacol Ther; 1998 May; 36(5):282-5. PubMed ID: 9629993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Average bioequivalence of two oral formulations of fluconazole in healthy subjects after multiple dosing.
    Atanasova I; Bozhinova K; Terziivanov D
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):282-5. PubMed ID: 10395119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of an adaptive group sequential design in a bioequivalence study.
    Bandyopadhyay N; Dragalin V
    Pharm Stat; 2007; 6(2):115-22. PubMed ID: 17436336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet.
    Karim A; Slater M; Bradford D; Schwartz L; Laurent A
    J Clin Pharmacol; 2007 Jan; 47(1):48-55. PubMed ID: 17192501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V; Della Paschoa O
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):418-25. PubMed ID: 9352390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies.
    Lacey LF; Keene ON; Duquesnoy C; Bye A
    J Pharm Sci; 1994 Feb; 83(2):212-5. PubMed ID: 8169791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
    Jackson AJ
    Pharm Res; 2000 Nov; 17(11):1432-6. PubMed ID: 11205739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992 Aug; 30(8):287-90. PubMed ID: 1526691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate.
    Basson RP; Ghosh A; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1998 Feb; 15(2):276-9. PubMed ID: 9523315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absorption rate vs. exposure: which is more useful for bioequivalence testing?
    Tozer TN; Bois FY; Hauck WW; Chen ML; Williams RL
    Pharm Res; 1996 Mar; 13(3):453-6. PubMed ID: 8692741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simulation study of the relationship between variation in bioavailability and clinical equivalence using a direct link model.
    Matsumoto Y; Shimizu M; Ogata H
    Int J Clin Pharmacol Ther; 2005 Jan; 43(1):57-62. PubMed ID: 15704616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitive and specific determination of the equivalence of absorption rates.
    Endrenyi L; Al-Shaikh P
    Pharm Res; 1995 Dec; 12(12):1856-64. PubMed ID: 8786956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.